19T.F IDORSIA AG

Healthcare Biotechnology Frankfurt Exchange
4.44 EUR
Close of Nov 12, 2026
3.18 8.09
Market cap
EUR 1.20B
P/E
-
P/B
6.32x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 19T.F undervalued?

Graham number

The Graham number of IDORSIA AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IDORSIA AG fundamental analysis

No fundamental analysis for IDORSIA AG yet.

IDORSIA AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IDORSIA AG

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a gl…

Full company profile